News | Robotic Systems | September 03, 2019

First-in-Human Telerobotic Coronary Intervention Procedures Published in EClinicalMedicine

Journal in The Lancet family publishes successful clinical results of remote PCI procedures using CorPath GRX Robotic System technology

First-in-Human Telerobotic Coronary Intervention Procedures Published in EClinicalMedicine

September 3, 2019 — Corindus Vascular Robotics Inc. announced that EClinicalMedicine, a clinical journal published by The Lancet, has published the results from the Telerobotic Intervention Study, the world’s first percutaneous coronary intervention (PCI) procedures conducted from a remote location outside the catheterization lab. The study was conducted using Corindus’ CorPath technology platform.

The paper, titled Long Distance Telerobotic-Assisted Percutaneous Coronary Intervention: First-in-Human Experience, discusses five successful patient cases performed by Tejas Patel, M.D., chairman and chief interventional cardiologist of the Apex Heart Institute in Ahmedabad, Gujarat, India. The five patients featured in the paper underwent elective PCI procedures from a distance of approximately 20 miles (32 kilometers) from Patel’s location inside the Swaminarayan Akshardham temple in Gandhinagar, Gujarat, India. His partner, Sanjay Shah, M.D., was onsite in the room with each patient at the Apex Heart Institute.

“I am honored to have been a part of this medical milestone,” stated Patel. “The application of telerobotics for remote treatment has the potential to impact a significant number of lives by providing access to specialized care that may not otherwise be possible. I am pleased to share my experience with the clinical community in such a well-respected publication that is part of the Lancet family,” added Patel.

Corindus developed the remote telerobotic interventional platform to deliver highly specialized and timely cardiovascular care to underserved patient populations with geographic barriers to treatment. The company is working on product development to enable use of the CorPath System in remote interventions and expand the company’s robotic platform to address stroke care.

For more information: www.corindus.com

 

Related Content

Corindus CorPath Used in World's First-in-Human Telerobotic Coronary Intervention

Corindus Vascular Robotics to Be Acquired by Siemens Healthineers

 

Reference

1. Patel T.M., Shah S.C., Pancholy S.B. Long Distance Tele-Robotic-Assisted Percutaneous Coronary Intervention: A Report of First-in-Human Experience. EClinicalMedicine, published online Sept. 3, 2019. https://doi.org/10.1016/j.eclinm.2019.07.017

Related Content

Videos | Cath Lab | April 02, 2021
Corindus, a Siemens Healthineers company and a developer of vascular robotics, recently launched a new set of automat
Videos | Cath Lab | March 31, 2021
This is a quick example of clinical use of the Shockwave Medical Intravascular Lithotripsy system that uses sonic wav

SpectraWave is developing a a new intravascular imaging system that combines two currently available modalities. This likely includes optical coherence tomography (OCT), left, which can define structures within the vessel and vessel wall.  Near infrared spectroscopy (NIRS), right, enables a spectral chemical analysis of the vessel walls to show areas of high lipid content, and specifically can identify lipid-core plaques that are associated with heart attack-causing plaque ruptures.

News | Cath Lab | February 16, 2021
February 16, 2021 – SpectraWave Inc.
Videos | Cath Lab | February 04, 2021
Cindy Grines, M.D., MSCAI, FACC, president
Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar